Abstract
BACKGROUND Genetic counseling in autosomal recessive Stargardt disease (STGD1) is complicated because of unknown frequencies of pathogenic ABCA4 alleles across populations, variable and unknown severity of ABCA4 alleles, and incomplete penetrance.
METHODS In this cross-sectional study, published ABCA4 variants were categorized by severity based on previous functional and clinical studies and current statistical comparisons of their frequencies in patients versus the general population, their observed versus expected homozygous occurrence in patients, and their occurrence in combination with established mild alleles in patients. The sum allele frequencies of these severity categories were used to estimate inheritance risks for offspring of STGD1 patients and carriers of pathogenic ABCA4 variants.
RESULTS The risk for offspring of a STGD1 patient with the ‘severe|severe’ genotype or a ‘severe|mild with complete penetrance’ genotype to develop STGD1 at some moment in life was estimated at 2.8-3.1% (1 in 35-32 individuals) and 1.6-1.8% (1 in 62-57 individuals), respectively. The risk to develop STGD1 in childhood was estimated to be 2 to 4-fold lower: 0.7-0.8% (1 in 148-124) and 0.3-0.4% (1 in 295-248), respectively. For offspring of an unaffected ABCA4 variant carrier from a STGD1 family who carries one severe or one mild ABCA4 variant with complete penetrance, the risk to develop STGD1 throughout life is 1.4-1.6% (1 in 71-64) and 0.19-0.21% (1 in 516-487), respectively.
CONCLUSION We propose a genotype-based personalized counseling approach to appreciate the large differences in inheritance risk between individuals. We advocate considering the lower risk of early-onset STGD1 compared with the total STGD1 risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding Esmee H. Runhart, Stephanie S. Cornelis, Zelia Corradi, Susanne Roosing and Frans P.M. Cremers were supported by the Foundation Fighting Blindness USA, grant BR-GE-0120-0775-LUMC, RetinaUK, grant no. GR591, the Fighting Blindness Ireland grant FB18CRE, and the Foundation Fighting Blindness USA, grant no. PPA-0517-0717-RAD, the Stichting Blindenhulp, the Stichting voor Ooglijders, and the Stichting tot Verbetering van het Lot der Blinden. C.M. Dhaenens was supported by Groupement de Cooperation Sanitaire Interregional G4 qui reunit les Centres Hospitaliers Universitaires Amiens, Caen, Lille et Rouen (GCS G4) and by the Fondation Stargardt France. Elfride De Baere, Frans P.M. Cremers, Susanne Roosing, Miriam Bauwens and Zelia Corradi were supported by European Union's Horizon 2020 research and innovation programme Marie Sklodowska-Curie Innovative Training Networks (ITN) StarT (grant No. 813490). Elfride De Baere, Frans P.M. Cremers, Susanne Roosing, Miriam Bauwens were supported by EJPRD19-234 (Solve-RET). Elfride De Baere is a Senior Clinical Investigator of the Research Foundation-Flanders (FWO) (1802220N). Elfride De Baere and Frans P.M. Cremers are members of the ERN-EYE consortium which is co-funded by the Health Program of the European Union under the Framework Partnership Agreement No. 739534-ERN-EYE. Elfride De Baere was supported by grants from Ghent University Special Research Fund (BOF20/GOA/023); FWO research project G0A9718N, Foundation JED, Foundation John W. Mouton Pro Retina. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Patient data have been uploaded to the LOVD ABCA4 database.
